A new EMA reflection paper reviews expectations for real-world data from non-interventional studies that are used to generate real-world evidence for regulatory purposes. The draft paper drills into specifics for sponsors, including considerations for bias assessment, data quality and statistical analysis.
Real-world data (RWD) are data generated through general clinical practice or from other sources outside the controlled environment of clinical trials.
Fill out the form to read the full article.
Required *